Providing that synthetic amylin agents as well as sCT products are already available for the treatment of diabetes [61], osteoporosis [62], and Paget’s disease [63], these or similar compounds render promising pharmacotherapiers for AUD. The gene discussed is IAPP; the disease is diabetes mellitus.